19 pharmaceutical funds have seen their net value increase by more than 10% this year.

Since the beginning of this year, many pharmaceutical funds have seen a significant increase in net value. According to Wind data, as of August 7, 19 pharmaceutical funds have recorded a net value increase of over 10% this year, with the highest increase approaching 25%. Classified by type, actively managed pharmaceutical funds have performed the best in terms of net value this year. The data shows that actively managed pharmaceutical funds occupy all top ten positions in the increase rankings, with China Merchants Pharmaceutical Health Industry leading the market with a nearly 25% increase in net value, followed closely by Penghua Innovation Pharmaceutical A with a 24% increase. Yongying Pharmaceutical Health A has also maintained a net value increase of over 20% this year. In addition, several products such as Guotai Pharmaceutical Health A, Huatai-Pb Pharmaceutical Healthcare A, Jiaoyin Pharmaceutical Innovation A, and Harvest Pharmaceutical Health A have seen net value increases ranging from 10% to 20%.